Ke Lin

Ke Lin

Auto-generated profile, based on publicly available information

Ke Lin

Department of Medical Ultrasonics, Institute of Diagnostic and Interventional Ultrasound, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 March 2026 in JHEP Reports
Verified
Journal Article
Open access
KLKe Lin
Ke Lin
JHJiayao Huang
Jiayao Huang
NZNan Zhang
Nan Zhang
BQBin Qiao
Bin Qiao
DYDaopeng Yang
Daopeng Yang
BZBowen Zhuang
Bowen Zhuang
Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality globally. Radiofrequency ablation (RFA) is a widely used treatment for HCC, but its efficacy is often limited by tumor relapse. Neutrophils, which serve as a double-edged sword in tumor immunology, have recently been implicated in antitumor immunity post RFA. Shear wave elastography (SWE) is a non-invasive examination of liver tissue and is associated with immune response. This study investigates the correlation between dynamic changes in SWE values and neutrophil response following RFA, and explores potential adjuvant strategies for RFA. We conducted a comprehensive analysis using both clinical data from patients undergoing RFA (n = 102) and experimental studies in mouse models (n = 4-6 per group). Single-cell RNA sequencing (scRNA-seq) and multi-omics analyses, including multiplex immunofluorescence staining and flow cytometric analysis, were performed to identify neutrophil subsets. To assess the therapeutic potential of neutrophil-activating therapy to enhance antitumor immunity post RFA, we tested a CD40 agonist in combination with RFA in preclinical models. Increasing liver SWE values following RFA were significantly associated with reduced relapse (n = 102, p <0.001), a phenomenon that was linked to the inflammatory environment induced by the infiltration of neutrophils (2.5-fold increase, p <0.001). scRNA-seq analysis identified neutrophil subsets characterized by high expression of IFN-stimulated genes, which exhibited potent antitumor activity via nitric oxide. Importantly, treatment with a CD40 agonist significantly augmented this immune response, leading to reduced tumor growth in mice (149.6 ± 38.12 mm3vs. 23.92 ± 4.43 mm3, p = 0.008). Our results linked clinical features to neutrophil-mediated immunity post RFA. Thus, neutrophil-activating therapies, such as CD40 agonists, could prevent HCC relapse after RFA. We report that increases in liver SWE are linked with neutrophil infiltration, providing a non-invasive biomarker for monitoring HCC relapse post RFA. Thus, pioneering innate immune modulators, such as CD40 agonists, could be viable adjuvant strategies following RFA.

1 March 2026 in JCO Precision Oncology
Verified
Journal Article
Closed access
KLKe Lin
Ke Lin
CWCailun Wang
Cailun Wang
BQBin Qiao
Bin Qiao
NZNan Zhang
Nan Zhang
DYDaopeng Yang
Daopeng Yang
BZBowen Zhuang
Bowen Zhuang
PURPOSE: This prospective study aimed to evaluate the prognostic significance of pretreatment KRAS -mutant circulating tumor DNA (ctDNA) in predicting recurrence incidence and patterns in patients with colorectal liver metastasis (CRLM) undergoing radiofrequency ablation (RFA). METHODS: Seventy-eight patients with CRLM treated with curative-intent RFA were enrolled. Pretreatment plasma ctDNA was analyzed using droplet digital polymerase chain reaction for KRAS mutations. Clinicopathologic data, recurrence patterns, and progression-free survival (PFS) were correlated with ctDNA and KRAS status. Transcriptomic profiling of tumor tissues was performed to explore biological mechanisms. RESULTS: Pretreatment ctDNA was detected positive in 26.9% (21/78) of patients. Patients who harbored KRAS -mutant ctDNA exhibited significantly higher recurrence rates (71.4% v 31.6%, P = .004) and shorter median PFS (352 days v not reached, P < .001). Multivariate Cox analysis confirmed that >3 hepatic lesions (adjusted hazard ratio [HR], 7.66 [95% CI, 2.70 to 21.8], P < .001) and positive ctDNA status (adjusted HR, 3.20 [95% CI, 1.60 to 6.42], P = .001) were independent predictors of recurrence. Moreover, ctDNA-positive patients predominantly developed lung metastases (60%), while ctDNA-negative patients showed liver-dominant recurrence (61.1%). Transcriptomic analysis linked ctDNA positivity to epithelial-mesenchymal transition and DNA repair pathways, with elevated nicotinamide N-methyltransferase expression correlating with aggressive phenotypes. CONCLUSION: Pretreatment KRAS -mutant ctDNA predicts higher recurrence risk and shows an association with lung-predominant metastasis in patients with CRLM after RFA. Integrating ctDNA and KRAS profiling enhances risk stratification and supports personalized surveillance strategies.

6 July 2026 in JHEP Reports
Verified
Journal Article
Open access
DYDaopeng Yang
Daopeng Yang
KLKe Lin
Ke Lin
YYYue Yang
Yue Yang
NZNan Zhang
Nan Zhang
BQBin Qiao
Bin Qiao
BZBowen Zhuang
Bowen Zhuang
After thermal ablation, patients with hepatocellular carcinoma (HCC) should undergo long-term surveillance for disease relapse. However, the optimal follow-up strategy remains unexplored. We retrospectively analyzed the clinical data of patients who received complete ablation for initial HCC within the Milan criteria from two tertiary hospitals in China. The Ranger model was applied to develop low- or high-risk stratification for recurrence according to the cutoff value of recurrence probability. The follow-up strategies for each stratification were developed based on monthly probability of recurrence and validated by internal bootstraps and external validation. In total, 1008 patients were included. Using a cutoff of 0.63 for the Ranger model-derived 2-year recurrence probability (based on GGT, AFP, age, tumor number, and tumor size), patients were classified as low risk (≤0.63) or high risk (>0.63). Based on the Ranger model, an optimal surveillance schedule was established to maximize the power of detecting recurrence and reduce the number of total visits. Risk-based strategies were validated by internal bootstrap resampling and an external cohort. The proposed strategy entailed 10 visits for low-risk patients (2 per year for years 1-5) and 12 visits for high-risk patients (5,4,1,1,1 in years 1-5), whereas the guideline-recommended fixed schedule called for 14 visits. The risk-based surveillance strategies reduced delayed detection time (DDT) compared to clinical guidelines. Detailed follow-up arrangements were available through an interactive website(http://fahultrasound.site:8622/pafah). Compared with the fixed guideline schedule, our risk-stratified surveillance strategy reduced patient burden through fewer follow-up visits and enhanced early detection of recurrence in both low-risk and high-risk patients. This strategy provides a valuable reference for clinicians and patients to standardize the follow-up strategy following local ablation. The Ranger model allows estimation of the prognosis of patients with early-stage HCC undergoing radical ablation and builds a risk-based follow-up strategy for individualized postoperative management. The risk-based follow-up strategy was more efficient in early detection of recurrence without increasing medical costs compared with guidelines. Our interactive website provides a valuable reference for both clinicians and patients to standardize the follow-up of HCC patients after local ablation.